Management of Hypertension in Hypertrophic Obstructive Cardiomyopathy

First‑Line Antihypertensive Therapy

Beta‑blockers are the preferred first‑line agents for treating hypertension in patients with obstructive or non‑obstructive hypertrophic obstructive cardiomyopathy (HOCM). The American College of Cardiology (ACC) recommends initiating therapy with a beta‑blocker and titrating to achieve a resting heart rate < 60–65 bpm, using maximum recommended doses when tolerated. [@1]
Caution is required when beta‑blockers are used in patients with sinus bradycardia or severe conduction disease. Monitoring for bradyarrhythmias and conduction abnormalities is advised. [@1][@3]

Verapamil may be used as an alternative when beta‑blockers are ineffective or contraindicated. Start at low dose and titrate up to ≈ 480 mg/day; this provides negative inotropic effects that can reduce LVOT gradients. [@1][@4]
Diltiazem is an option for patients who cannot tolerate verapamil or have a verapamil contraindication. [@5][@6]
Verapamil should be avoided in patients with very high resting gradients (> 80–100 mm Hg), advanced heart failure, systemic hypotension, or severe dyspnea at rest. [@1][@4][@2]
All non‑dihydropyridine calcium‑channel blockers should be initiated at low doses because their vasodilating properties can worsen outflow‑tract obstruction. [@2][@8]

Dihydropyridine calcium‑channel blockers (e.g., nifedipine, amlodipine) are potentially harmful in patients with resting or provocable LVOT obstruction and should be avoided. [@1][@3][@4][@6][@7]
Pure vasodilators and high‑dose diuretics can exacerbate obstruction and are contraindicated in this setting. [@5][@9]
ACE inhibitors and ARBs have uncertain benefit in HOCM with preserved systolic function and may be harmful in the presence of resting or provocable obstruction; they should be used only with extreme caution. [@1][@3][@4]
A 12‑month trial demonstrated that losartan can be used without clinically adverse consequences for other indications when needed, but its routine use in HOCM remains cautious. [@10]
Low‑dose diuretics may be added cautiously when congestive symptoms persist despite optimal beta‑blocker or calcium‑channel blocker therapy. [@1][@3][@4][@6]
Aggressive diuresis should be avoided because reducing preload can increase LVOT gradients. [@8][@11]

Patients should be evaluated for resting or provocable LVOT obstruction (gradient ≥ 30 mm Hg) before selecting antihypertensive therapy. [@1]
Initial therapy consists of a beta‑blocker, titrated to a resting heart rate < 60–65 bpm, with close monitoring for bradycardia and conduction abnormalities. [@1][@2][@4][@3]
If beta‑blockers are ineffective or contraindicated, switch to verapamil (low‑dose start, titrate to ≈ 480 mg/day) or diltiazem, avoiding use in patients with high gradients (> 80–100 mm Hg) or severe symptoms. [@1][@3][@2][@4]
Blood pressure should be closely monitored during initiation of verapamil or diltiazem to detect hypotension that could worsen obstruction. [@2]

Hypertension in HOCM should be treated in accordance with existing ACC hypertension guidelines, emphasizing a stepwise, symptom‑oriented approach. [@1][@3][@9]
Medications that promote outflow‑tract obstruction—such as pure vasodilators and high‑dose diuretics—must be eliminated from the regimen. [@2][@8]

Never prescribe dihydropyridine calcium‑channel blockers in symptomatic obstructive HOCM. [@1][@3][@4][@6][@7]
Do not initiate verapamil in patients with very high resting gradients or severe heart‑failure symptoms. [@1][@4][@2]
Avoid aggressive diuresis, which can worsen LVOT gradients by decreasing preload. [@8][@11]
Exercise caution when introducing any vasodilator therapy (ACE‑I, ARB) in patients with provocable obstruction. [@1][@3][@2][@8]